{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:12:17Z","timestamp":1787501537639,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-026-04003-z","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:03:54Z","timestamp":1771506234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Loading dose and 12-month outcomes in treatment-na\u00efve patients with neovascular age-related macular degeneration treated with faricimab, with AI-based analysis of fluid dynamics"],"prefix":"10.1007","volume":"46","author":[{"given":"Mickael","family":"Barbosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Bartolomeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannic Pannatier","family":"Schuetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C.","family":"Nascimbeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Gallo","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou Path\u00e9","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Ambresin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"issue":"1","key":"4003_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","volume":"4","author":"TA Ciulla","year":"2020","unstructured":"Ciulla TA, Hussain RM, Pollack JS, Williams DF (2020) Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes. Ophthalmol Retina 4(1):19\u201330. https:\/\/doi.org\/10.1016\/j.oret.2019.05.017","journal-title":"Ophthalmol Retina"},{"issue":"12","key":"4003_CR2","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","volume":"5","author":"SR Flaxman","year":"2017","unstructured":"Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, Das A, Jonas JB, Keeffe J, Kempen JH, Leasher J, Limburg H, Naidoo K, Pesudovs K, Silvester A, Stevens GA, Tahhan N, Wong TY, Taylor HR (2017) Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health 5(12):e1221\u2013e1234. https:\/\/doi.org\/10.1016\/S2214-109X(17)30393-5","journal-title":"Lancet Glob Health"},{"issue":"10326","key":"4003_CR3","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399(10326):729\u2013740. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"issue":"11","key":"4003_CR4","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G (2016) Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med 8(11):1265\u20131288. https:\/\/doi.org\/10.15252\/emmm.201505889","journal-title":"EMBO Mol Med"},{"key":"4003_CR5","unstructured":"U.S. food and drug administration VABYSMO (2025) Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761235s000lbl.pdf. Accessed January 15 2025"},{"key":"4003_CR6","unstructured":"European medicines agency (2022) Vabysmo. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vabysmo-epar-product-information_en.pdf. Accessed January 15 2025"},{"issue":"2","key":"4003_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/bjo-2022-322297","volume":"108","author":"R Martin-Pinardel","year":"2024","unstructured":"Martin-Pinardel R, Izquierdo-Serra J, De Zanet S, Parrado-Carrillo A, Garay-Aramburu G, Puzo M, Arruabarrena C, Sararols L, Abraldes M, Broc L, Escobar-Barranco JJ, Figueroa M, Zapata MA, Ruiz-Moreno JM, Moll-Udina A, Bernal-Morales C, Alforja S, Figueras-Roca M, Gomez-Baldo L, Ciller C, Apostolopoulos S, Mosinska A, Casaroli Marano RP, Zarranz-Ventura J (2024) Artificial intelligence-based fluid quantification and associated visual outcomes in a real-world, multicentre neovascular age-related macular degeneration national database. Br J Ophthalmol 108(2):253\u2013262. https:\/\/doi.org\/10.1136\/bjo-2022-322297","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"4003_CR8","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.10.4.17","volume":"10","author":"I Mantel","year":"2021","unstructured":"Mantel I, Mosinska A, Bergin C, Polito MS, Guidotti J, Apostolopoulos S, Ciller C, De Zanet S (2021) Automated quantification of pathological fluids in neovascular age-related macular degeneration, and its repeatability using deep learning. Transl Vis Sci Technol 10(4):17. https:\/\/doi.org\/10.1167\/tvst.10.4.17","journal-title":"Transl Vis Sci Technol"},{"issue":"7","key":"4003_CR9","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori NZ, Feuer W, Rosenfeld PJ (2010) Novel method for analyzing snellen visual acuity measurements. Retina 30(7):1046\u20131050. https:\/\/doi.org\/10.1097\/IAE.0b013e3181d87e04","journal-title":"Retina"},{"issue":"8","key":"4003_CR10","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s40123-024-00980-5","volume":"13","author":"E Giancipoli","year":"2024","unstructured":"Giancipoli E, Guglielmi A, Bux AV, Clima GME, Pignatelli F, Boscia F, Viggiano P, Boscia G, Fortunato F, Besozzi G, Niro A, Dore S, Iaculli C (2024) Real-world outcomes of a loading phase with intravitreal faricimab in neovascular age-related macular degeneration (n-AMD) and diabetic macular edema (DME). Ophthalmol Ther 13(8):2163\u20132184. https:\/\/doi.org\/10.1007\/s40123-024-00980-5","journal-title":"Ophthalmol Ther"},{"issue":"17","key":"4003_CR11","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, Haug SJ, London NJS, Mein L, Sheth VS, Wolfe JD, Singer MA, Danzig CJ (2023) The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study-6\u00a0month results. Eye Lond 37(17):3574\u20133581. https:\/\/doi.org\/10.1038\/s41433-023-02553-5","journal-title":"Eye Lond"},{"issue":"1","key":"4003_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62559-1","volume":"14","author":"R Mukai","year":"2024","unstructured":"Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, Watanabe Y, Yamamoto A, Wakatsuki Y, Onoe H, Wakugawa S, Terao N, Hasegawa T, Kawai M, Maruko R, Itagaki K, Honjo J, Okada AA, Mori R, Koizumi H, Iida T, Sekiryu T (2024) One-year outcomes and safety assessment of faricimab in treatment-naive patients with neovascular age-related macular degeneration in Japan. Sci Rep 14(1):11681. https:\/\/doi.org\/10.1038\/s41598-024-62559-1","journal-title":"Sci Rep"},{"key":"4003_CR13","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2147\/OPTH.S463624","volume":"18","author":"NQX Quah","year":"2024","unstructured":"Quah NQX, Javed KMMA, Arbi L, Hanumunthadu D (2024) Real-world outcomes of faricimab treatment for neovascular age-related macular degeneration and diabetic macular edema. Clin Ophthalmol 18:1479\u20131490. https:\/\/doi.org\/10.2147\/OPTH.S463624","journal-title":"Clin Ophthalmol"},{"issue":"15","key":"4003_CR14","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","volume":"37","author":"PE Stanga","year":"2023","unstructured":"Stanga PE, Valent\u00edn-Bravo FJ, Stanga SEF, Reinstein UI, Pastor-Idoate S, Downes SM (2023) Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye 37(15):3282\u20133289. https:\/\/doi.org\/10.1038\/s41433-023-02505-z","journal-title":"Eye"},{"issue":"10","key":"4003_CR15","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1007\/s40123-024-01005-x","volume":"13","author":"D Veritti","year":"2024","unstructured":"Veritti D, Sarao V, Gonfiantini M, Rubinato L, Lanzetta P (2024) Faricimab in neovascular AMD complicated by pigment epithelium detachment: an AI-assisted evaluation of early morphological changes. Ophthalmol Ther 13(10):2813\u20132824. https:\/\/doi.org\/10.1007\/s40123-024-01005-x","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"4003_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/aos.13565","volume":"96","author":"M Ashraf","year":"2018","unstructured":"Ashraf M, Souka A, Adelman RA (2018) Age-related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmol 96(2):120\u2013133. https:\/\/doi.org\/10.1111\/aos.13565","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"4003_CR17","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.oret.2023.02.008","volume":"7","author":"K Xue","year":"2023","unstructured":"Xue K, Hua P, Maguire MG, Daniel E, Jaffe GJ, Grunwald JE, Ying GS (2023) Prediction for 2-year vision outcomes using early morphologic and functional responses in the comparison of age-related macular degeneration treatments trials. Ophthalmol Retina 7(7):564\u2013572. https:\/\/doi.org\/10.1016\/j.oret.2023.02.008","journal-title":"Ophthalmol Retina"},{"key":"4003_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2147\/OPTH.S448507","volume":"18","author":"A Tanaka","year":"2024","unstructured":"Tanaka A, Hata M, Tsuchikawa M, Ueda-Arakawa NU, Tamura H, Miyata M, Takahashi A, Kido A, Muraoka Y, Miyake M, Ooto S, Tsujikawa A (2024) Short-term outcomes of 3\u00a0monthly intravitreal faricimab on different subtypes of neovascular age-related macular degeneration. Clin Ophthalmol 18:507\u2013516. https:\/\/doi.org\/10.2147\/OPTH.S448507","journal-title":"Clin Ophthalmol"},{"issue":"11","key":"4003_CR19","doi-asserted-by":"publisher","first-page":"e0314167","DOI":"10.1371\/journal.pone.0314167","volume":"19","author":"IB Pfister","year":"2024","unstructured":"Pfister IB, Schild C, Garweg JG (2024) Predicting long-term functional anti-VEGF treatment outcomes in neovascular AMD in a real-world setting. PLoS ONE 19(11):e0314167. https:\/\/doi.org\/10.1371\/journal.pone.0314167","journal-title":"PLoS ONE"},{"issue":"1","key":"4003_CR20","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1111\/aos.15219","volume":"101","author":"M Schranz","year":"2023","unstructured":"Schranz M, Told R, Hacker V, Reiter GS, Reumueller A, Vogl WD, Bogunovic H, Sacu S, Schmidt-Erfurth U, Roberts PK (2023) Correlation of vascular and fluid-related parameters in neovascular age-related macular degeneration using deep learning. Acta Ophthalmol 101(1):e95\u2013e105. https:\/\/doi.org\/10.1111\/aos.15219","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"4003_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000529930","volume":"14","author":"CR Clemens","year":"2023","unstructured":"Clemens CR, Alten F, Zimmermann JA, Eter N (2023) Old problem in a new guise: retinal pigment epithelium tear after intravitreal faricimab (Vabysmo\u00ae) injection. Case Rep Ophthalmol 14(1):241\u2013244. https:\/\/doi.org\/10.1159\/000529930","journal-title":"Case Rep Ophthalmol"},{"issue":"4","key":"4003_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.survophthal.2017.03.004","volume":"62","author":"MG Ersoz","year":"2017","unstructured":"Ersoz MG, Karacorlu M, Arf S, Sayman Muslubas I, Hocaoglu M (2017) Retinal pigment epithelium tears: classification, pathogenesis, predictors, and management. Surv Ophthalmol 62(4):493\u2013505. https:\/\/doi.org\/10.1016\/j.survophthal.2017.03.004","journal-title":"Surv Ophthalmol"},{"key":"4003_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/aos.70000","author":"A Eidenberger","year":"2025","unstructured":"Eidenberger A, Reiter GS, Mares V, Frank-Publig S, Fuchs P, Baratsits M, Gumpinger M, Faustmann G, Miere A, Creuzot-Garcher C, Scheschy U, Kodjikian L, Gualino V, Wolff B, Sacu S, Schmidt-Erfurth U (2025) Fluid\/function correlation using AI-based quantification versus central subfield thickness in treatment-naive and pre-treated patients with neovascular AMD in a real-world setting. Acta Ophthalmol. https:\/\/doi.org\/10.1111\/aos.70000","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"4003_CR24","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/bjo-2022-323014","volume":"108","author":"V Mares","year":"2024","unstructured":"Mares V, Schmidt-Erfurth UM, Leingang O, Fuchs P, Nehemy MB, Bogunovic H, Barthelmes D, Reiter GS (2024) Approved AI-based fluid monitoring to identify morphological and functional treatment outcomes in neovascular age-related macular degeneration in real-world routine. Br J Ophthalmol 108(7):971\u2013977. https:\/\/doi.org\/10.1136\/bjo-2022-323014","journal-title":"Br J Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04003-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-04003-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04003-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T01:05:04Z","timestamp":1771549504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-026-04003-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4003"],"URL":"https:\/\/doi.org\/10.1007\/s10792-026-04003-z","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The other authors declare no proprietary or commercial interests with regard to any of the content discussed in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"124"}}